fbpx

Eli Lilly, Sanofi, and Novo Nordisk Questioned About ‘Unacceptably High’ Insulin Prices

Last month, House Energy and Commerce Committee leaders sent letters to the executives at Eli Lilly, Sanofi, and Novo Nordisk expressing their concern over the “unacceptably high” insulin prices. The committee first inquired about the topic in 2019. Now, they want to know what actions these companies have taken since then in an effort to decrease the cost.

Insulin Prices 10 Times Higher in U.S.

According to the letters, written by committee chair Frank Pallone (D-NJ) and subcommittee chair Diana DeGette (D-CO), the price of insulin in the United States is more than 10 times that of 33 other countries. The leaders are pushing to decrease the cost of the diabetes treatment — a particularly important endeavor considering that these three companies control 99 percent of the world’s insulin supply. 

Specifically, Pallone and DeGette shared that many of the 34 million American diabetes patients are without the option of insulin due to its price. “We are committed to increasing access to affordable medicines and fighting the rising cost of insulin,” the Democratic leaders wrote. “Given your company’s representations in 2019 that this is a shared concern, we are interested in learning what has been done to alleviate this issue since that time.”

Specific Requests of Committee Leaders

The Committee leaders requested more information from Eli Lilly, Sanofi, and Novo Nordisk by September 17th. They asked for an explanation of any list or net price increases as well as the gross revenue and net profit by product and year. Additionally, they want a description of the steps the companies have taken to improve accessibility and decrease cost. Lastly, they asked for an explanation of the effect of the COVID-19 pandemic on any products. 

Also, in the note to Sanofi CEO Paul Hudson, lawmakers reference a 2021 pricing report from the drug manufacturer, which states that the average out-of-pocket costs for insulin users have increased 82 percent since 2012.

For more information about the high cost of insulin, contact us today.

Additional Reading:

Novo Nordisk Recalls Samples of Insulin Medication for Diabetes

Novo Nordisk Recalls Samples of Insulin Medication for Diabetes

The Food and Drug Administration (FDA) announced that global healthcare company Novo Nordisk has voluntarily recalled samples of its insulin medication taken for diabetes, a health condition that affects over 34 million people in the United States alone. 

The company recently recalled nearly 1,500 samples of Levemir®, Tresiba®, Fiasp®, NovoLog®, and Xultophy® — all insulin products that are prescribed to lower a diabetes patient’s blood glucose levels. It was also revealed that all recalled items “are packaged in cartons with either a vial, pen-injector (FlexPen® or FlexTouch®) or a cartridge (PenFill®).” The company stresses that use of a recalled product sample may not deliver the correct dosage, possibly leading to “hyperglycemia or hypoglycemia resulting in adverse health consequences ranging from limited to life-threatening.”

The samples were not stored within the correct temperature ranges, which can cause diminished product efficacy. Fierce Pharma reports that the issues occurred during the winter storm power outages in Texas earlier this year as well as due to human error in physician offices. With about 1.5 million samples in-market, this recall affects 0.1 percent of samples from Novo Nordisk. 

For more information about this recall, contact us today.

Drug Law Journal Legal Sponsorship

Drug Law Journal's publishing and research are sponsored by the DDP Injury Law Group in Washington, D.C. Their legal team is focused on protecting the rights of injury victims.
Furthermore, they understand and appreciate the importance of a trusted attorney-client relationship.
The DDP Injury Law Group uses their years of experience with litigation to ensure their clients can fight for the compensation they deserve.

Always seek the advice of a medical professional when making personal health choices.

The Offices of DrugLawJournal.com are located at:

1800 North Orange Avenue, Suite C
Orlando, Florida 32804

DrugLawJournal.com is sponsored by the DDP Injury Law Group, and therefore may be considered attorney advertising. The information contained on DrugLawJournal.com is provided for informational purposes only, and should not be construed as legal or medical advice on any subject matter. No viewers of this site should discontinue taking a prescribed medication on the basis of any information on this site and should always first consult with a doctor concerning any medication. Viewers should understand that if they refrain from taking prescribed medication without appropriate medical advice they can suffer injury or death.

No viewers of content from this site, clients or otherwise, should act or refrain from acting on the basis of any content included in the site without seeking the appropriate legal or other professional advice on the particular facts and circumstances at issue from an attorney licensed in the viewer’s state. Viewing information from DrugLawJournal.com does not create an attorney-client relationship between you and DDP Injury Law Group or DrugLawJournal.com nor is it intended to do so.The content of DrugLawJournal.com may not reflect current legal developments, verdicts or settlements. Prior results do not predict a similar outcome. For more information, please visit our web site’s disclaimer.

©2024 DrugLawJournal.com | Privacy Policy | Terms & Conditions

Stay Informed

Sign up to receive peroidic updates from our expert team of researchers, highlighting defective drugs, devices, and legal issues related to your health.

Email Catcher
Free Drug and Medical Device Case Review

Free Drug and Medical Device Case Review

Share your story with us and we will reach out to you about your case.

First
Last
Described what happened to you, we will review and reach out to you about your situation.

It is important for those who have suffered injury from dangerous drugs and medical devices to know that they have may have options.

Consumers have the ability to seek legal remedies for their injuries resulting from the negligence of drug and device manufacturers. The first step toward justice and recovery is sharing your story with effective legal counsel. An attorney will help you to better understand the issues and discuss the possibility of compensation for your suffering.

Once you complete the information request above, Drug Law Journal will send the information to a specialist at our legal sponsor’s firm, the DDP Injury Law Group, in Washington, D.C. That specialist will follow-up with you directly to gather further specific information about your case and make an evaluation. If the firm is able to move forward on your case, they will also discuss next steps. Remember – the entire consult and evaluation is free to you. You only need to take the first step to fill out the contact form or call: (800) 597-1870 for immediate assistance.